<DOC>
	<DOCNO>NCT00048295</DOCNO>
	<brief_summary>ISIS 2302 antisense oligonucleotide drug reduces production specific protein call intercellular adhesion molecule ( ICAM-1 ) , substance play significant role increase inflammation . People Crohn ’ disease show over-produce ICAM-1 gut tissue . Alicaforsen work block ICAM-1 messenger RNA , “ instruction ” molecule require production ICAM-1 protein . This trial examine effect alicaforsen deliver 2-hour intravenous infusion four-week period , compare placebo . Patients may remain stable background 5-ASA , antibiotic , immunosuppressive drug , prednisone ( equivalent ) &lt; /= 30 mg per day .</brief_summary>
	<brief_title>Alicaforsen ( ISIS 2302 ) Patients With Active Crohn ’ Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Alicaforsen</mesh_term>
	<criteria>Inclusion Criteria 1 . Age &gt; /= 12 year 2 . Weight &gt; /= 36 kg 3 . CDAI score 220 – 400 4 . Documentation Crohn ’ disease activity endoscopy , biopsy image last 2 year 5 . No TNFα inhibitor treatment three month prior first study drug infusion Exclusion Criteria 1 . Known severe , fix , symptomatic stenosis small large intestine significant dilation 2 . Extensive external fistulization ( &gt; 3 external fistula expressible gentle compression ) ; colostomy ileostomy 3 . Active infection , include infectious colitis , infection HIV , Hepatitis B Hepatitis C 4 . Malignancy within 3 year poorly control medical illness 5 . Requires intravenous heparin therapy history bleeding problem</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
</DOC>